Breast Cancer Research and Treatment

, Volume 165, Issue 1, pp 151–159 | Cite as

Fertility preservation with ovarian stimulation and time to treatment in women with stage II–III breast cancer receiving neoadjuvant therapy

  • A. Jo ChienEmail author
  • Julia Chambers
  • Fiona Mcauley
  • Tessa Kaplan
  • Joseph Letourneau
  • Jimmy Hwang
  • Mi-Ok Kim
  • Michelle E. Melisko
  • Hope S. Rugo
  • Laura J. Esserman
  • Mitchell P. Rosen



To determine whether fertility preservation with ovarian stimulation (OS) results in treatment delay in breast cancer (BC) patients receiving neoadjuvant therapy (NAT).


This is a retrospective study of women screened for the prospective neoadjuvant ISPY2 trial at the University of California San Francisco. All patients were <43, had stage II–III BC, and received neoadjuvant therapy. Time to initiation of NAT was compared between women who underwent OS (STIM) and women who did not (control). Patient and tumor characteristics, as well as oncologic outcomes, were compared between STIM and control groups.


82 patients were included (34 STIM and 48 control). STIM patients were overall younger (mean = 35 vs. 36.9 years old, p = 0.06), and more likely to be childless (79.4 vs 31.2%, p < 0.0001) than controls. Mean time from diagnosis to initiation of NAT was 40 days, with no significant difference between STIM and control groups (mean 39.8 days vs 40.9 days, p = 0.75). Mean time from diagnosis to fertility consultation was 16.3 days. With median follow-up of 79 months, 16 (19.5%) patients have recurred or died from BC. Rates of pCR, recurrence, and death were similar in both groups. Six of 34 STIM patients have undergone embryo transfer, resulting in one patient with two live births.


Fertility preservation with OS can be performed in the neoadjuvant setting without delay in initiation of systemic therapy and should be discussed with all early-stage BC patients of reproductive age.


Fertility preservation Ovarian stimulation Neoadjuvant Breast cancer Treatment delay Time to chemotherapy 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Research involving human rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Trivers KF, Fink AK, Partridge AH, Oktay K, Ginsburg ES, Li C, Pollack LA (2014) Estimates of young breast cancer survivors at risk for infertility in the U.S. Oncologist 19(8):814–822. doi: 10.1634/theoncologist.2014-0016 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Mathews TJ, Hamilton BE (2016) Mean age of mothers is on the rise: United States, 2000-2014. NCHS Data Brief 232:1–8Google Scholar
  3. 3.
    Duffy CM, Allen SM, Clark MA (2005) Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 23(4):766–773. doi: 10.1200/JCO.2005.01.134 CrossRefPubMedGoogle Scholar
  4. 4.
    Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104(5):386–405. doi: 10.1093/jnci/djr541 CrossRefPubMedGoogle Scholar
  5. 5.
    Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer EP (2004) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22(20):4174–4183. doi: 10.1200/JCO.2004.01.159 CrossRefPubMedGoogle Scholar
  6. 6.
    Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R (2007) The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 30(2):126–132. doi: 10.1097/01.coc.0000251398.57630.4f CrossRefPubMedGoogle Scholar
  7. 7.
    Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L, Group GIMS (2015) Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. Jama 314(24):2632–2640. doi: 10.1001/jama.2015.17291 CrossRefPubMedGoogle Scholar
  8. 8.
    Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS, Investigators PS (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372(10):923–932. doi: 10.1056/NEJMoa1413204 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K, American Society of Clinical O (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510. doi: 10.1200/JCO.2013.49.2678 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Azim AA, Costantini-Ferrando M, Oktay K (2008) Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 26(16):2630–2635. doi: 10.1200/JCO.2007.14.8700 CrossRefPubMedGoogle Scholar
  11. 11.
    Baynosa J, Westphal LM, Madrigrano A, Wapnir I (2009) Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg 209(5):603–607. doi: 10.1016/j.jamcollsurg.2009.08.006 CrossRefPubMedGoogle Scholar
  12. 12.
    Kim J, Turan V, Oktay K (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 101(4):1364–1371. doi: 10.1210/jc.2015-3878 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26(5):778–785. doi: 10.1200/JCO.2007.15.0235 CrossRefPubMedGoogle Scholar
  14. 14.
    Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7):2483–2493. doi: 10.1200/JCO.1997.15.7.2483 CrossRefPubMedGoogle Scholar
  15. 15.
    Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172. doi: 10.1016/S0140-6736(13)62422-8 CrossRefPubMedGoogle Scholar
  16. 16.
    Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281. doi: 10.1200/JCO.2007.14.4147 CrossRefPubMedGoogle Scholar
  17. 17.
    Park JW, Liu MC, Yee D, Yau C, van’t Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, Investigators IS (2016) Adaptive randomization of neratinib in early breast cancer. N Engl J Med 375(1):11–22. doi: 10.1056/NEJMoa1513750 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rugo HS, Olopade OI, DeMichele A, Yau C, van’t Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, Investigators IS (2016) Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 375(1):23–34. doi: 10.1056/NEJMoa1513749 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA (1982) Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 2(2):163–169CrossRefPubMedGoogle Scholar
  20. 20.
    Cold S, During M, Ewertz M, Knoop A, Moller S (2005) Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer 93(6):627–632. doi: 10.1038/sj.bjc.6602734 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Jara Sanchez C, Ruiz A, Martin M, Anton A, Munarriz B, Plazaola A, Schneider J, del Prado PM, Alba E, Fernandez-Aramburo A (2007) Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat 101(2):215–223. doi: 10.1007/s10549-006-9282-0 CrossRefPubMedGoogle Scholar
  22. 22.
    Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A (2005) Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 23(9):1934–1940. doi: 10.1200/JCO.2005.04.032 CrossRefPubMedGoogle Scholar
  23. 23.
    Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735–744. doi: 10.1200/JCO.2013.49.7693 CrossRefPubMedGoogle Scholar
  24. 24.
    Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH (2016) Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2(3):322–329. doi: 10.1001/jamaoncol.2015.3856 CrossRefPubMedGoogle Scholar
  25. 25.
    Engel J, Eckel R, Kerr J, Schmidt M, Furstenberger G, Richter R, Sauer H, Senn HJ, Holzel D (2003) The process of metastasisation for breast cancer. Eur J Cancer 39(12):1794–1806CrossRefPubMedGoogle Scholar
  26. 26.
    Folkman J (1990) Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev 9(3):171–174CrossRefPubMedGoogle Scholar
  27. 27.
    Sanford RA LX, Giordano SH, Tripathy D, Barcenas CH, Chavez-Mac Gregor M (2016) Impact of delayed neoadjuvant systemic chemotherapy on survival outcomes in breast cancer patients. J Clin Oncol 34(suppl):abstr 1038Google Scholar
  28. 28.
    Sonmezer M, Turkcuoglu I, Coskun U, Oktay K (2011) Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 95(6):2125-e2129. doi: 10.1016/j.fertnstert.2011.01.030 CrossRefGoogle Scholar
  29. 29.
    Cakmak H, Rosen MP (2015) Random-start ovarian stimulation in patients with cancer. Curr Opin Obstet Gynecol 27(3):215–221. doi: 10.1097/GCO.0000000000000180 CrossRefPubMedGoogle Scholar
  30. 30.
    Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP (2017) Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. doi: 10.1093/humrep/dew355 PubMedGoogle Scholar
  31. 31.
    Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F (2015) Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 33(22):2424–2429. doi: 10.1200/JCO.2014.59.3723 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • A. Jo Chien
    • 1
    Email author
  • Julia Chambers
    • 2
  • Fiona Mcauley
    • 1
  • Tessa Kaplan
    • 3
  • Joseph Letourneau
    • 4
  • Jimmy Hwang
    • 1
  • Mi-Ok Kim
    • 1
  • Michelle E. Melisko
    • 1
  • Hope S. Rugo
    • 1
  • Laura J. Esserman
    • 1
  • Mitchell P. Rosen
    • 4
  1. 1.Helen Diller Family Comprehensive Cancer CenterUniversity of California San FranciscoSan FranciscoUSA
  2. 2.University of California San Francisco School of MedicineFranciscoUSA
  3. 3.Columbia University College of Physicians and SurgeonsNew YorkUSA
  4. 4.Department of Obstetrics, Gynecology and Reproductive SciencesUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations